The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan

Vincent Chin-Hung Chen¹,², Yao-Hsu Yang³,⁴,⁵,⁶, Yin-To Liao⁷,⁸, Ting-Yu Kuo⁴, Hsin-Yi Liang²,⁹, Kuo-You Huang¹⁰, Yin-Cheng Huang¹¹, Yena Lee¹², Roger S. McIntyre¹²,¹³, Tzu-Chin Lin⁶,⁷,*

¹ Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital, Chiayi County, Taiwan, ² Department of Medicine, School of Medicine, Chang Gung University, Tao-Yuan, Taiwan, ³ Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan, ⁴ Center of Excellence for Chang Gung Research Datalink, Chang Gung Memorial Hospital, Chiayi, Taiwan, ⁵ Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan, ⁶ School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁷ Department of Psychiatry, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁸ Department of Psychiatry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ⁹ Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰ Department of Speech, Language Pathology and Audiology, Chung Shan Medical University, Taichung, Taiwan, ¹¹ Department of Neurosurgery, Chang Gung Memorial Hospital, Chiayi, ¹² Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Canada, ¹³ Department of Psychiatry, University of Toronto, Toronto, Canada

* jamaalbest@gmail.com

Abstract

Attention-deficit hyperactivity disorder (ADHD) is associated with higher risk for fracture. Whether the medical treatment for ADHD would mitigate the risk remains unclear. In this study, we sought to investigate the effect of methylphenidate treatment on risk for fracture, as well the moderational role of treatment duration on the risk of fracture, in a large national sample. Cases less than 18 years old were identified from Taiwan’s National Health Insurance Research Database with a new primary diagnosis of ADHD (ICD-9:314) between 1996 and 2013. A total of 6201 cases with ADHD were included as the study cohort. The cases were divided into 3 groups according to the duration of methylphenidate treatment (0, 1–180, and more than 180 days). All groups were followed until the end of 2013 for first diagnoses of fracture (ICD-9 codes 800 to 829). Cox proportional hazards models were applied. Compared to the group without methylphenidate treatment, the risk for fracture was lower among the group treated for more than 180 days. The adjusted hazard ratio was 0.77 (95% Confidence interval: 0.63–0.94). The groups treated for 180 days or fewer had no significant difference in the risk for fracture. In conclusion, methylphenidate treatment was associated with lower risk for fracture among ADHD patients. The association was evident only in the cohort treated for more than 180 days.
Introduction

Attention-deficit hyperactivity disorder (ADHD) is a neuropsychiatric condition characterized by hyperactivity, impulsivity, and cognitive dysfunction [1]. The typical age at onset of ADHD is during childhood and adolescence with an estimated 10–30% of affected individuals continuing to manifest symptoms during adulthood [2, 3]. The global lifetime prevalence of ADHD is estimated to be 5.29% [4]. Patients with ADHD often have significant impairment in academic functioning as well as in social and interpersonal domains [5–7]. In addition, accumulating evidence indicates that ADHD is associated with increased risk for accidental physical injuries, such as motor vehicle accidents and traumatic brain injuries [8–12]. The core symptoms of ADHD including inattention, distractibility, and impulsivity likely account for the increased risk for unintentional self-harm [13].

The impact of ADHD medication also received growing attention as well. The study by van den Ban et al revealed that the incidence rate for injuries during exposure to ADHD drugs was lower in the exposed period compared to the period prior to ADHD drug use [14]. Another self-controlled case series study demonstrated that the ADHD medication had a preventive effect on the risk of brain injuries (34% risk reduction) [15]. Furthermore, the study by Lange et al reported that ADHD-affected youngsters had higher risks for accidents than their unaffected counterparts and the medication intake was only a weak predictor for accidents [16]. These studies tried to explore the role of ADHD medication on the risk for different kinds of injuries. These results could not be compared directly owing to the different study designs and different outcomes (e.g. injuries, brain injuries, and accidents).

Within the broad category of unintentional self-harm or injuries among children and adolescent, fracture is a well-defined diagnosis. The injuries from fracture are common and further add to the illness-associated morbidity in ADHD [17–21]. Two recently published population-based studies in Taiwan provide empirical evidence that, in the general population, ADHD is highly associated with fracture in children and adolescents [22, 23]. Notwithstanding the association between ADHD and risk of unintentional injury, relatively few studies have evaluated whether exposure to psychostimulant treatment mitigates the risk. Moreover, it is also not known whether the duration of psychostimulant exposure moderates the possible injury-lowering effects of psychostimulants.

Despite unequivocal evidence documenting efficacy across core symptoms of ADHD [24], insufficient medical treatment duration is a common problem resulting in inadequate treatment response among ADHD cases [25–27]. The National survey in Taiwan by Gau et al also indicated that poor adherence was associated with more severe ADHD-related symptoms [28]. The high rate of treatment non-adherence to psychostimulants invites the need to clarify whether the duration of exposure to stimulants mitigates any salutary effects.

Herein, we primarily aimed to determine, by using a nationwide population-based dataset in Taiwan, the effect of psychostimulant prescription for ADHD on mitigating the risk of fracture, and whether the mitigating effects are moderated by the duration of exposure among cases less than 18 years old.

Materials and methods

Sample

This retrospective cohort study utilized data from the Taiwan National Health Insurance Research Database (NHIRD) under the aegis of the National Health Research Institute (NHRI) which included outpatient, ambulatory, hospital inpatient care, as well as dental services. The National Health Insurance (NHI) program provides compulsory universal health
insurance, implemented in March 1995, covering all delivery of health care in 99.5% of the national population. In cooperation with the Bureau of NHI, the NHRI extracted a randomly sampled representative database of 1,000,000 people from the registry of all NHI enrollees using a systematic sampling method for research purposes, forming the Longitudinal Health Insurance Database (LHID). There are no statistically significant differences in age, sex, or health care costs between this sample and all enrollees [29].

ADHD cases were identified based on recorded International Classification of Disease, Ninth revision (ICD-9) codes of 314. All medical claims made under this diagnostic code between 1996 and 2013 were collected from NHIRD for further analysis. The definition of ADHD for this analysis required an inpatient diagnosis or two outpatient diagnoses during one year. Using the foregoing definition, 9826 ADHD cases between 1996 and 2013 were identified. Cases born before 1996 or after 2005, fracture before ADHD diagnosis, missing residential data, or ADHD diagnosis within one year prior to study period were excluded. Total 6201 cases of ADHD comprised the final study cohort.

In Taiwan, methylphenidate was the only stimulant approved for ADHD treatment during 1996 to 2013, including short- and sustained-release preparations. The two preparations of methylphenidate had similar effects on ADHD symptoms, but the sustained-release preparation was more convenient with lesser rebound side effects [30, 31]. Atomoxetine, a non-stimulant, was also approved as a medication for ADHD in Taiwan since 2007. The approved ages for both methylphenidate and atomoxetine are 6 and older in Taiwan. Methylphenidate is recommended by the Taiwan National Health Insurance as a first-line treatment for ADHD. Atomoxetine is recommended for the treatment of ADHD in cases where methylphenidate treatment results in insufficient treatment outcomes (i.e. inefficacy, intolerability). It can be reasonably assumed that atomoxetine exposures have had prior exposure to methylphenidate treatment. As atomoxetine is not a psychostimulant and we were primarily interested in psychostimulant risk mitigation, we confined our analysis to those cases that were prescribed with methylphenidate only. Cases with both methylphenidate and Atomoxetine prescriptions had been excluded. Furthermore, ADHD cases in Taiwan might have received both immediate and sustained-release preparations of methylphenidate during different periods of their clinical course. Therefore, we sought to determine the influence of the duration of methylphenidate exposure, regardless of their pharmacological formulations, by evaluating groups according to three separate duration intervals.

The treatment intervals chosen were 0, 1–180, and more than 180 days respectively. It was based on several epidemiological studies revealing that most ADHD cases received medical treatment for less than 180 days [32–34]. The effects of treatment duration exceeding 180 days deserved exploration. The treatment duration was defined as the cumulative length of methylphenidate exposure (days) within the follow-up time until fracture, death, or end of study period. The length of exposure was cumulated whether the prescriptions were continuous or interrupted. All groups were followed for incidence of fracture as an outcome, which was defined on the basis of ICD-9 codes 800–829. Individuals with fracture were identified if he/she had two or more outpatient diagnoses in the same year or any inpatient diagnosis.

Covariates considered in this analysis were chosen a priori on the basis of hypothetical associations with the exposure and outcome of interest. These comprised several demographic factors such as sex, age and urbanized level of residence [35]. Comorbid conditions associated with the risk for fracture were also considered, including seizure (ICD-9 code 345) [36–38], asthma (ICD-9 code 493) [39–42], intellectual disability (ICD-9 codes 317–319) [43, 44], autism (ICD-9 code 299) [45, 46], benzodiazepine (BZD) or hypnotic use [47], and conduct disorder (ICD-9 code 312) [48]. The definitions of asthma, seizure, intellectual disability, autism and conduct disorder were based on two or more outpatient diagnoses in the same
year or any inpatient diagnosis. The BZD/hypnotic use referred to any prescription of the medications (ATC codes N05B, N05C) during the follow-up period.

The NHIRD consists of de-identified secondary data released to the public for research purposes. This study had been reviewed and approved by the Institutional Review Board of Chung Shan Medical University Hospital.

**Statistical analysis**

The distribution of demographic factors and the proportions of comorbidities between the three groups with different treatment duration of methylphenidate were compared. Cox proportional hazards models were used to compute the hazard ratios (HRs) accompanying 95% confidence intervals (CIs) after adjustment for sex, age, urbanized level of residence, seizure, asthma, intellectual disability, autism, BZD/hypnotic use, and conduct disorder. Two-tailed \( P = 0.05 \) was considered significant. Patients with a death date in the admission file and those withdrawn from the registry for beneficiaries were censored. All of these analyses were conducted using SAS statistical software (Version 9.4; SAS Institute, Cary, NC, USA).

**Result**

**Characteristics of subjects**

The study cohort comprised 6201 cases with ADHD. The characteristics of the three groups with different treatment duration of methylphenidate are described and compared in Table 1.

The differences of demographic characters between three groups were sex, age, urbanized level of residence, and follow-up duration. The group with medication for more than 180 days had the highest male/female ratio (83.6%/16.4%). Most cases were between 6–11 years old and the mean age was lowest in the group without methylphenidate treatment (6.90 ± 2.69). Most cases were from the area of moderate to high level of urbanization and the group without methylphenidate treatment had the least cases from the least urbanized area (3.5%). The follow-up duration was longest in the group with methylphenidate treatment for more than 180 days (5.75 ± 2.79 years).

Three groups have no significant difference in the rates of comorbid seizure, asthma, intellectual disability, autism, and BZD/hypnotic use. The group with methylphenidate treatment for more than 180 days had the highest rate of comorbid conduct disorder (3.8%). The incidence of fracture was significantly different among three groups: 9.5% (0 day), 11.3% (1–180 days), and 8.7% (more than 180 days) respectively.

**Association between methylphenidate treatment and the risk for fracture**

Analysis of methylphenidate treatment and the risk of fracture is shown in Table 2. Compared to the group without methylphenidate treatment, the group with exposure of 1–180 days did not have a reduced risk for fracture. For those received treatment lasting more than 180 days, the risk for fracture was significantly lower than the reference group (HR 0.77, CI 0.63–0.94) in multivariate analysis. Several significant risks of fracture also existed in multivariate analysis including male sex, older age, and asthma.

**Discussion**

To our knowledge, this is the first study that has investigated the effect of medical treatment for ADHD, and the moderational role of treatment duration, on risk for fracture. The findings revealed that methylphenidate treatment exceeding 180 days or greater was linked to nearly
25% lower risk for fracture comparing to those never received methylphenidate. In addition, shorter duration of medical treatment did not mitigate risk for fracture. Relatively few studies have evaluated the effect of psychostimulants on bone health. The cohort study by Chou et al. reported that ADHD was associated a 1.32 times greater likelihood of fractures [22]. They also reported that compared to children without ADHD, the untreated ADHD group had a significantly increased risk for fracture (HR 1.64, 95% CI 1.37–1.96). However, amongst individuals with ADHD who were treated with stimulants, there were no significant between-group differences in risk for fracture when compared to the healthy group (HR 1.12, 95% CI 0.97–1.29). The foregoing collection of observations suggests that psychostimulant prescription mitigates the risk of fracture, but, unfortunately, data were not provided on whether the treatment duration further moderated risk reduction.

Another recent retrospective cohort study also reported that medication for ADHD was associated with lower risk of fracture [49]. They compared cases with two or more prescriptions for an ADHD medication with those without medication. Individuals without medication had a significantly increased hazard of fracture (HR: 3.9, CI: 2.6–5.9). A risk-reduction

Table 1. Characteristics of groups with different treatment duration of methylphenidate.

| Variables               | Methylphenidate |
|-------------------------|-----------------|
|                         | 0 day (N = 2,623) | 1–180 days (N = 1,742) | >180 days (N = 1,836) |
|                         | count (%) | count (%) | count (%) |
| Sex                     |           |           |           |
| Female                  | 664 (25.3%) | 338 (19.4%) | 301 (16.4%) |
| Male                    | 1,959 (74.7%) | 1,404 (80.6%) | 1,535 (83.6%) |
| Age                     | 6.90 ± 2.69 | 8.10 ± 2.65 | 7.53 ± 2.42 |
| Urbanized level of residence |     |           |           |
| 1 (City)                | 983 (37.5%) | 592 (34.0%) | 665 (36.2%) |
| 2                       | 1,262 (48.1%) | 829 (47.6%) | 842 (45.9%) |
| 3                       | 285 (10.9%) | 210 (12.1%) | 215 (11.7%) |
| 4 (Villages)            | 93 (3.5%) | 111 (6.4%) | 114 (6.2%) |
| Covariates              |           |           |           |
| Seizure                 | 82 (3.1%) | 60 (3.4%) | 76 (4.1%) |
| Asthma                  | 834 (31.8%) | 550 (31.6%) | 610 (33.2%) |
| Intellectual disability | 126 (4.8%) | 98 (5.6%) | 117 (6.4%) |
| Autism                  | 115 (4.4%) | 78 (4.5%) | 73 (4.0%) |
| Conduct disorder        | 55 (2.1%) | 57 (3.3%) | 70 (3.8%) |
| BZD/hypnotic use        | 767 (29.2%) | 527 (30.3%) | 586 (31.9%) |
| Fracture                | 248 (9.5%) | 196 (11.3%) | 159 (8.7%) |
| Follow-up duration (year) | 5.33 ± 3.20 | 4.90 ± 3.02 | 5.75 ± 2.79 |

https://doi.org/10.1371/journal.pone.0173762.t001
The role of ADHD medication was also revealed in this study, but the role of treatment duration was still unclear.

In our study, we explored the role of the methylphenidate treatment duration on the risk for fracture. The group receiving methylphenidate for more than 180 days had significantly lower risk for fracture when compared to the group without methylphenidate treatment (HR 0.77, CI 0.63–0.94). A protective role of pharmacotherapy in the prevention of fracture was inferred. Moreover, the protective effect was observed only in cohort with exposure >180 days. Amongst individuals receiving methylphenidate for 1–180 days, the risk for fracture had

Table 2. Cox’s proportional hazards model for the risk of fracture*.

| Variables                  | Frequency | Univariate           | Multivariate          |
|----------------------------|-----------|----------------------|-----------------------|
|                            | count (%) | HR 95%CI P value     | HR 95%CI P value      |
| Methylphenidate            |           |                      |                       |
| 0 day(ref.)                | 2,623 (42.3%) | 1.00 | 1.00                   |
| 1–180 days                 | 1,742 (28.1%) | 1.29 | 1.07–1.56 0.007 | 1.18 | 0.98–1.43 0.087 |
| >180 days                  | 1,836 (29.6%) | 0.84 | 0.69–1.03 0.096 | 0.77 | 0.63–0.94 0.011 |
| Sex                        |           |                      |                       |
| Female(ref.)               | 1,303 (21.0%) | 1.00 | 1.00                   |
| Male                       | 4,898 (79.0%) | 1.83 | 1.44–2.32 <.001 | 1.83 | 1.44–2.32 <.0001 |
| Age                        |           |                      |                       |
| 0–5 (ref.)                 | 1,406 (22.7%) | 1.00 | 1.00                   |
| 6–11                       | 4,282 (69.1%) | 1.28 | 1.06–1.55 0.010 | 1.22 | 1.00–1.48 0.046 |
| 12–18                      | 513 (8.3%) | 2.05 | 1.42–2.96 <.001 | 1.96 | 1.35–2.86 0.000 |
| Urbanized level of residence |          |                      |                       |
| 1 (City) (ref.)           | 2,240 (36.1%) | 1.00 | 1.00                   |
| 2                          | 2,933 (47.3%) | 1.18 | 0.92–1.52 0.190 | 1.18 | 0.99–1.42 0.065 |
| 3                          | 710 (11.4%) | 1.27 | 0.88–1.82 0.200 | 1.17 | 0.90–1.54 0.244 |
| 4 (Villages)               | 318 (5.1%) | 0.80 | 0.43–1.50 0.490 | 1.31 | 0.91–1.89 0.150 |
| Covariates                 |           |                      |                       |
| Seizure                    |           |                      |                       |
| No (ref.)                  | 5,983 (96.5%) | 1.00 | 1.00                   |
| Yes                        | 218 (3.5%) | 1.12 | 0.76–1.66 0.570 | 1.16 | 0.78–1.74 0.464 |
| Asthma                     |           |                      |                       |
| No (ref.)                  | 4,207 (67.8%) | 1.00 | 1.00                   |
| Yes                        | 1,994 (32.2%) | 1.25 | 1.06–1.48 0.009 | 1.21 | 1.03–1.44 0.025 |
| Intellectual disability    |           |                      |                       |
| No (ref.)                  | 5,860 (94.5%) | 1.00 | 1.00                   |
| Yes                        | 341 (5.5%) | 0.78 | 0.53–1.15 0.212 | 0.81 | 0.55–1.21 0.306 |
| Autism                     |           |                      |                       |
| No (ref.)                  | 5,935 (95.7%) | 1.00 | 1.00                   |
| Yes                        | 266 (4.3%) | 0.69 | 0.45–1.06 0.090 | 0.72 | 0.46–1.11 0.138 |
| Conduct disorder           |           |                      |                       |
| No (ref.)                  | 6,019 (97.1%) | 1.00 | 1.00                   |
| Yes                        | 182 (2.9%) | 0.68 | 0.52–1.45 0.178 | 0.65 | 0.37–1.15 0.140 |
| BZD/hypnotic use           |           |                      |                       |
| No (ref.)                  | 4,321 (69.7%) | 1.00 | 1.00                   |
| Yes                        | 1,880 (30.3%) | 1.13 | 0.95–1.33 0.170 | 1.05 | 0.88–1.24 0.624 |

* adjusting for sex, age, urbanized level of residence, seizure, asthma, intellectual disability, autism, conduct disorder and BZD/hypnotic use

https://doi.org/10.1371/journal.pone.0173762.t002
no significant difference compared to those without methylphenidate treatment. That is, the treatment duration moderated the risk reduction.

Our results replicate the risk mitigation effect reported by Chou or Perry et al. Our results, however, further extend knowledge by identifying duration of exposure as a critical moderational factor. The exact mechanism was unknown. We conjecture that the salutary effects of stimulants are possibly mediated by improved cognitive function (e.g. reduced impulsivity). In previous studies, the increased risk for fracture in ADHD patients had been accounted by the core symptoms including impulsivity, recklessness, hyperactivity, and distractibility in daily life [50]. The children with ADHD have more risky behavior and might neglect the safety precaution during activities. Several interventional studies in ADHD have reported an accrual of benefit across core target symptoms in ADHD throughout sufficient duration of treatment [51]. It is possible that the medical treatment reduces the symptoms severity and further lessens the risk for fracture once the treatment duration lasts more than 180 days.

The main outcome in our study was fracture. Comparing with several recent studies on the association between ADHD, medication, and different types of injuries [14–16], our result also revealed that the ADHD medication (e.g. methylphenidate) had a possible role in injury prevention. Other significant risks for fracture in our analysis were male sex, age, and asthma. Male sex was associated with higher risk for fracture in our multivariate analysis (HR: 1.83, CI: 1.44–2.32). In previous literature, boys were more likely to have all injuries than girls generally [52]. Male sex had also been identified as a risk for injuries among ADHD population [53]. We had similar result regarding the sex difference in the risk for fracture.

The risk for fracture increased with ages among our study population. This finding was consistent with previous studies [53]. Among ADHD population, adolescents had a higher risk for injury than children.

In multivariate analysis, asthma was associated with higher risk for fracture (HR 1.21, CI 1.03–1.44). It was consistent with previous studies regarding the risk of fracture in asthma cases [42, 54, 55]. The exact mechanism was unclear despite several hypotheses had been proposed [56]. Corticosteroids, as one of the treatments for asthma, had detrimental effects on bone health [57]. Glucocorticoid-induced osteoporosis might be one of the possible mechanisms but further studies will be needed to clarify the exact relationship between asthma and fracture [55, 58].

The findings from our study have several important public health and therapeutic implications. From the aspect of public health, pharmacotherapy should be considered as an important strategy for preventing fracture-related dysfunction among young ADHD patient. In our study cohort, only 29.6% of ADHD cases received methylphenidate for more than 180 days. For clinicians, the need for sufficient treatment duration of pharmacotherapy should be addressed to the patients as well as their parents. Moreover, the interplay of ADHD, fracture, and pharmacotherapy merits further researches.

**Strengths and limitations**

To our knowledge, this is the first study using a nationally representative sample and longitudinal dataset to investigate the relationship between methylphenidate prescription and risk for fracture. Our use of a cross-national, highly inclusive, representative database would be less susceptible to selection and recall bias. The observation that duration of exposure is significantly influenced by risk mitigation is directly consistent with the hypothesis that methylphenidate treatment is the critical intervention influencing our dependent variable.

There are several methodological limitations that affect inferences and interpretations of our data. First, the exact adherence of methylphenidate was unknown. Second, the severity of
ADHD was not evaluated, quantified, and/or measured. The severity of symptoms between
groups with different treatment duration could not be compared or adjusted in the following
analysis. Furthermore, we are unable to ascertain whether fracture risk reduction correlates
with a reduction in overall ADHD psychopathology severity. Last, several confounding factors
were not available in NHIRD dataset including, but not limited to, lifestyle and body mass
index. It is also unknown whether other medications or interventions had a similar impact, or
moderational effects, on the fracture risk reduction seen with methylphenidate.

Conclusion

Methylphenidate treatment decreased the risk for fracture amongst individuals with ADHD.
The risk reduction is observed in individuals with longer treatment duration (i.e. >180 days).
The high lifetime prevalence and persistence of ADHD, as well as the personal and economic
costs associated with fracture and other unintentional injuries, underscores the public health
significance of this topic. Moreover, adjudicating risk and benefits of psychostimulants in
ADHD need to take into consideration both conventional measures (e.g. ADHD psychopa-
thology), as well as the impact on real-world outcomes.

Acknowledgments

The authors would like to thank Center of Excellence for Chang Gung Research Datalink
(CORPG6D0162) for the comments and assistance in data analysis.

Author Contributions

Conceptualization: VCHC TCL.
Data curation: YHY TYK.
Formal analysis: YTL HYL KYH YCH.
Funding acquisition: VCHC.
Investigation: VCHC TCL YHY TYK.
Methodology: VCHC.
Project administration: TCL.
Software: YHY.
Supervision: VCHC.
Validation: YL RSM.
Writing – original draft: TCL.
Writing – review & editing: YTL HYL KYH YCH YL RSM.

References

1. Sadock BJ, Sadock VA, Ruiz P. Attention Deficit/Hyperactivity Disorder. KAPLAN & SADOCK’S Synop-
sis of Psychiatry, 11th edition. 2015.
2. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and corre-
lates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. The
American journal of psychiatry. 2006; 163(4):716–23. Epub 2006/04/06. PubMed Central PMCID:
PMCPMC2859878. https://doi.org/10.1176/appi.ajp.163.4.716 PMID: 16585449
3. Huang CL, Chu CC, Cheng TJ, Weng SF. Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. PloS one. 2014; 9(4):e95014. Epub 2014/04/17. PubMed Central PMCID: PMC3988191. https://doi.org/10.1371/journal.pone.0095014 PMID: 24736469

4. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. The American journal of psychiatry. 2007; 164(6):942–8. Epub 2007/06/02. https://doi.org/10.1176/appi.ajp.2007.164.6.942 PMID: 17541055

5. Nijmeejr JS, Minderra RB, Buitelaar JK, Mulligan A, Hartman CA, Hoekstra PJ. Attention-deficit/hyperactivity disorder and social dysfunctioning. Clinical psychology review. 2008; 28(4):692–708. Epub 2007/11/27. https://doi.org/10.1016/j.cpr.2007.10.003 PMID: 18036711

6. Rogers M, Hwang H, Toplak M, Weiss M, Tannock R. Inattention, working memory, and academic achievement in adolescents referred for attention deficit/hyperactivity disorder (ADHD). Child neuropsychology: a journal on normal and abnormal development in childhood and adolescence. 2011; 17(5):444–58. Epub 2011/03/11.

7. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. Journal of the American Academy of Child and Adolescent Psychiatry. 2006; 45(2):192–202. Epub 2006/01/24. https://doi.org/10.1097/01.chi.0000189134.97436.e2 PMID: 16429090

8. Allun C, Guven G, Akgun OM, Aickel C. Dental injuries and attention-deficit/hyperactivity disorder in children. Special care in dentistry: official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry. 2012; 32(5):184–9.

9. Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Advances in medical sciences. 2009; 54(1):20–6. https://doi.org/10.2478/v10039-009-0022-7 PMID: 19586835

10. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). European archives of psychiatry and clinical neuroscience. 2006; 256 Suppl 1:26–31.

11. Ertan C, Ozcan OO, Pepele MS. Pediatric trauma patients and attention deficit hyperactivity disorder: correlation and significance. Emergency medicine journal: EMJ. 2012; 29(11):911–4. https://doi.org/10.1111/jemermed-2011-200298 PMID: 22215173

12. Tai YM, Gau SS, Gau CS. Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan. Research in developmental disabilities. 2013; 34(3):1100–8. https://doi.org/10.1016/j.ridd.2012.11.027 PMID: 23340027

13. Cairney J. Deficits in attention, motor control, and perception and increased risk of injury in children. Developmental medicine and child neurology. 2014; 56(11):1040–1. https://doi.org/10.1111/dmcn.12509 PMID: 24920215

14. van den Ban E, Souverein P, Meijer W, van Engeland H, Swaab H, Egberts T, et al. Association between ADHD drug use and injuries among children and adolescents. European child & adolescent psychiatry. 2014; 23(2):95–102. Epub 2013/06/05.

15. Mikolajczyk R, Hom J, Schmedt N, Langner I, Lindemann C, Garbe E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA pediatrics. 2015; 159(4):391–5. Epub 2015/02/17. https://doi.org/10.1001/jamapediatrics.2014.3275 PMID: 25686215

16. Lange H, Buse J, Bender S, Siegent J, Knopf H, Roessner V. Accident Proneness in Children and Adolescents Affected by ADHD and the Impact of Medication. Journal of attention disorders. 2016; 20(6):501–9. Epub 2014/01/29. https://doi.org/10.1177/1087054713518237 PMID: 24470540

17. Erdogan M, Deste1 EE, Imren Y, Yuce M, Buyukcoran I, Karadeniz E. Is attention deficit and hyperactivity disorder a risk factor for sustaining fractures of proximal humerus? Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca. 2014; 81(3):221–6. PMID: 24945391

18. Ozer K, Gillani S, Williams A, Hak DJ. Psychiatric risk factors in pediatric hand fractures. Journal of pediatric orthopaedics. 2010; 30(4):324–7. https://doi.org/10.1097/BPO.0b013e3181d8fa8e PMID: 20502230

19. Uluo MM, Uluo R. Extremity fracture characteristics in children with impulsive/hyperactive behavior. Archives of orthopaedic and trauma surgery. 2008; 128(4):417–21. https://doi.org/10.1007/s00402-007-0393-9 PMID: 17624536

20. Uluo M, Uluo R, Eksigolü F, Özen NE. Children with fractures show higher levels of impulsive-hyperactive behavior. Clinical orthopaedics and related research. 2007; 463:192–5. https://doi.org/10.1097/BLO.0b013e31805002da PMID: 17353797

21. Nakanjida A, Sakuraba K, Hurwitz EL. Pediatric orthopaedic injuries requiring hospitalization: epidemiology and economics. Journal of orthopaedic trauma. 2014; 28(3):167–72. https://doi.org/10.1097/BOT.0b013e318299cd20 PMID: 23681411
22. Chou IC, Lin CC, Sung FC, Kao CH. Attention-deficit-hyperactivity disorder increases risk of bone fracture: a population-based cohort study. Developmental medicine and child neurology. 2014; 56(11):1111–6. https://doi.org/10.1111/dmcn.12501 PMID: 24867299

23. Guo NW, Lin CL, Lin CW, Huang MT, Chang WL, Lu TH, et al. Fracture risk and correlating factors of a pediatric population with attention deficit hyperactivity disorder: a nationwide matched study. Journal of pediatric orthopedics Part B. 2015. Epub 2015/11/03.

24. Vaughan B, Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child and adolescent psychiatric clinics of North America. 2012; 21(4):941–55. Epub 2012/10/09. https://doi.org/10.1016/j.chc.2012.07.005 PMID: 23040908

25. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgraduate medicine. 2010; 122(1):184–91. Epub 2010/01/29. https://doi.org/10.3810/pgm.2010.01.2112 PMID: 20107302

26. Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Current psychiatry reports. 2013; 15(7):371. Epub 2013/05/29. PubMed Central PMCID: PMCPMC3718999. https://doi.org/10.1007/s11920-013-0371-6 PMID: 23712722

27. Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS drugs. 2014; 28(2):121–9. Epub 2014/01/10. https://doi.org/10.1007/s40263-013-0370-7 PMID: 24402970

28. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. The Journal of clinical psychiatry. 2008; 69(1):131–40. Epub 2008/03/04. PMID: 18312048

29. Institutes NHR. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan 2013. Available from: http://nhird.nhri.org.tw/date_01.html.

30. Durand-Rivera A, Alatorre-Miguel E, Zambrano-Sanchez E, Reyes-Legorreta C. Methylphenidate Efficacy: Immediate versus Extended Release at Short Term in Mexican Children with ADHD Assessed by Conners Scale and EEG. Neurology research international. 2015; 2015:207801. Epub 2015/04/04. PubMed Central PMCID: PMCPMC4369942. https://doi.org/10.1155/2015/207801 PMID: 25838946

31. Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ open. 2013; 3(3). Epub 2013/03/19. PubMed Central PMCID: PMCPMC3612754.

32. Chen CY, Yeh HH, Chen KH, Chang IS, Wu EC, Lin KM. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology. 2011; 21(3):265–73. Epub 2011/06/15. https://doi.org/10.1089/cap.2010.0107 PMID: 21663429

33. Garbe E, Mikolajczyk RT, Banaschewski T, Petermann U, Petermann F, Kraut AA, et al. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study. Journal of child and adolescent psychopharmacology. 2012; 22(6):452–8. Epub 2012/12/14. PubMed Central PMCID: PMCPMC3528251. https://doi.org/10.1089/cap.2012.0022 PMID: 23294588

34. Hong M, Kim B, Hwang JW, Bhang SY, Choi HY, Oh IH, et al. Naturalistic Pharmacotherapy Compliance among Pediatric Patients with Attention Deficit/Hyperactivity Disorder: a Study Based on Three-Year Nationwide Data. Journal of Korean medical science. 2016; 31(4):611–6. Epub 2016/04/07. PubMed Central PMCID: PMCPMC4810346. https://doi.org/10.3346/jkms.2016.31.4.611 PMID: 27051247

35. Lin YJ, Tian WH, Chen CC. Urbanization and the utilization of outpatient services under National Health Insurance in Taiwan. Health policy (Amsterdam, Netherlands). 2011; 103(2–3):236–43. Epub 2011/09/17.

36. Seidenberg M, Pulsipher DT, Hermann B. Association of epilepsy and comorbid conditions. Future neurology. 2009; 4(5):663–8. PubMed Central PMCID: PMC2802344. https://doi.org/10.2217/fnl.09.32 PMID: 20161538

37. Wirrell EC. Epilepsy-related injuries. Epilepsia. 2006; 47 Suppl 1:79–86.

38. Rheims S, Herbillon V, Villeneuve N, Auvin S, Napuri S, Canoes C, et al. ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate. Epilepsia. 2016. Epub 2016/05/31.

39. Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between AD and attention deficit hyperactivity disorder in US Children and Adults. The British journal of dermatology. 2016. Epub 2016/04/24.

40. Tsai CJ, Chou PH, Cheng C, Lin CH, Lan TH, Lin CC. Asthma in patients with attention-deficit/hyperactivity disorder: a nationwide population-based study. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists. 2014; 26(4):254–60. Epub 2014/11/18.
41. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Asthma and attention-deficit/hyperactivity disorder: a nationwide population-based prospective cohort study. Journal of child psychology and psychiatry, and allied disciplines. 2013; 54(11):1208–14. Epub 2013/06/05. https://doi.org/10.1111/jcpp.12087 PMID: 23730913

42. Melton LJ 3rd, Patel A, Achenbach SJ, Oberg AL, Yunginger JW. Long-term fracture risk among children with asthma: a population-based study. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2005; 20(4):564–70.

43. Fernandez-Jaen A. [Attention deficit hyperactivity disorder and mental retardation]. Revista de neurologia. 2006; 42 Suppl 2:S25–7. Epub 2006/03/24.

44. Center J, Beange H, McElduff A. People with mental retardation have an increased prevalence of osteoporosis: a population study. American journal of mental retardation: AJMR. 1998; 103(1):19–28. Epub 1998/07/25. https://doi.org/10.1352/0895-8017(1998)103<0019:PWMRHA>2.0.CO;2 PMID: 9678227

45. Neumeyer AM, O’Rourke JA, Massa A, Lee H, Lawson EA, McDougle CJ, et al. Brief report: bone fractures in children and adults with autism spectrum disorders. Journal of autism and developmental disorders. 2015; 45(3):881–7. https://doi.org/10.1007/s10803-014-2228-1 PMID: 25193141

46. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert review of neurotherapeutics. 2008; 8(4):657–69. Epub 2008/04/18. https://doi.org/10.1586/14737175.8.4.657 PMID: 18416666

47. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics and sedatives and risk of fractures: effects of half-life. Calcified tissue international. 2008; 82(1):34–43. Epub 2008/01/05. https://doi.org/10.1007/s00223-007-9095-0 PMID: 18175030

48. Loder RT, Warschauksy S, Schwartz EM, Hensinger RN, Greenfield ML. The psychosocial characteristics of children with fractures. Journal of pediatric orthopedics. 1995; 15(1):41–6. Epub 1995/01/01. PMID: 7883926

49. Perry BA, Archer KR, Song Y, Ma Y, Green JK, Elefteriou F, et al. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016; 27(7):2223–7. Epub 2016/03/02.

50. blondis TA. Motor disorders and attention-deficit/hyperactivity disorder. Pediatric clinics of North America. 1999; 46(5):899–913, vi-vii. PMID: 10570695

51. Gazer-Snitzovsky M, Brand-Gotheff A, Dubnov-Raz G, Weizman A, Gothelf D. High Familial Correlation in Methylphenidate Response and Side Effect Profile. Journal of attention disorders. 2015. Epub 2015/04/23.

52. Spady DW, Saunders DL, Schopflocher DP, Svenson LW. Patterns of injury in children: a population-based approach. Pediatrics. 2004; 113(3 Pt 1):S22–9. Epub 2004/03/03.

53. Marcus SC, Wan GJ, Zhang HF, Olfsen M. Injury among stimulant-treated youth with ADHD. Journal of attention disorders. 2008; 12(1):64–9. Epub 2007/10/16. https://doi.org/10.1177/1087054707305168 PMID: 17934179

54. Yeh FJ, Grant AM, Williams SM, Goulding A. Children who experience their first fracture at a young age have high rates of fracture. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2006; 17(2):267–72.

55. Liang W, Chikritzhs T, Lee AH. Is asthma associated with increased risk of injury? The Journal of asthma: official journal of the Association for the Care of Asthma. 2011; 48(3):311–5.

56. Gatti D, Senna G, Viapiana O, Rossini M, Passalacqua G, Adami S. Allergy and the bone: unexpected relationships. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2011; 107(3):202–6.

57. Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. The open respiratory medicine journal. 2014; 8:85–92. PubMed Central PMCID: PMC4319192. https://doi.org/10.2174/1874306401408010085 PMID: 25674178

58. Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. The Journal of allergy and clinical immunology. 2013; 132(5):1019–30. https://doi.org/10.1016/j.jaci.2013.08.040 PMID: 24176682